Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GHA plus azacitidine in elderly acute myeloid leukemia
ChiCTR2000032256Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of azacitidine, homoharringtonine, cytarabine and granulocyte colony-stimulating factor in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Complete remission rate, Complete remission with incomplete blood count recovery rate and 1 more. Started May 2020; status: recruiting.
02
Drugs
azacitidinehomoharringtoninecytarabinegranulocyte colony-stimulating factor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000032256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032256.